Immunogenicity and protective efficacy in mice and hamsters of a β-propiolactone inactivated whole virus SARS-CoV vaccine.
Identifieur interne : 002523 ( Main/Exploration ); précédent : 002522; suivant : 002524Immunogenicity and protective efficacy in mice and hamsters of a β-propiolactone inactivated whole virus SARS-CoV vaccine.
Auteurs : Anjeanette Roberts [États-Unis] ; Elaine W. Lamirande ; Leatrice Vogel ; Benoît Baras ; Geneviève Goossens ; Isabelle Knott ; Jun Chen ; Jerrold M. Ward ; Ventzislav Vassilev ; Kanta SubbaraoSource :
- Viral immunology [ 1557-8976 ] ; 2010.
Descripteurs français
- KwdFr :
- Adjuvants immunologiques (administration et posologie), Analyse de survie, Animaux, Anticorps antiviraux (sang), Anticorps neutralisants (sang), Cricetinae, Désinfectants (pharmacologie), Femelle, Foie (anatomopathologie), Inactivation virale, Mesocricetus, Poumon (anatomopathologie), Propiolactone (pharmacologie), Rappel de vaccin (), Souris, Souris de lignée BALB C, Syndrome respiratoire aigu sévère (), Syndrome respiratoire aigu sévère (immunologie), Vaccination (), Vaccins antiviraux (immunologie), Vaccins inactivés (immunologie), Virus du SRAS (immunologie).
- MESH :
- administration et posologie : Adjuvants immunologiques.
- anatomopathologie : Foie, Poumon.
- immunologie : Syndrome respiratoire aigu sévère, Vaccins antiviraux, Vaccins inactivés, Virus du SRAS.
- pharmacologie : Désinfectants, Propiolactone.
- sang : Anticorps antiviraux, Anticorps neutralisants.
- Analyse de survie, Animaux, Cricetinae, Femelle, Inactivation virale, Mesocricetus, Rappel de vaccin, Souris, Souris de lignée BALB C, Syndrome respiratoire aigu sévère, Vaccination.
English descriptors
- KwdEn :
- Adjuvants, Immunologic (administration & dosage), Animals, Antibodies, Neutralizing (blood), Antibodies, Viral (blood), Cricetinae, Disinfectants (pharmacology), Female, Immunization, Secondary (methods), Liver (pathology), Lung (pathology), Mesocricetus, Mice, Mice, Inbred BALB C, Propiolactone (pharmacology), SARS Virus (immunology), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (prevention & control), Survival Analysis, Vaccination (methods), Vaccines, Inactivated (immunology), Viral Vaccines (immunology), Virus Inactivation.
- MESH :
- chemical , administration & dosage : Adjuvants, Immunologic.
- chemical , blood : Antibodies, Neutralizing, Antibodies, Viral.
- chemical , immunology : Vaccines, Inactivated, Viral Vaccines.
- chemical , pharmacology : Disinfectants, Propiolactone.
- immunology : SARS Virus, Severe Acute Respiratory Syndrome.
- methods : Immunization, Secondary, Vaccination.
- pathology : Liver, Lung.
- prevention & control : Severe Acute Respiratory Syndrome.
- Animals, Cricetinae, Female, Mesocricetus, Mice, Mice, Inbred BALB C, Survival Analysis, Virus Inactivation.
Abstract
The immunogenicity and efficacy of β-propiolactone (BPL) inactivated whole virion SARS-CoV (WI-SARS) vaccine was evaluated in BALB/c mice and golden Syrian hamsters. The vaccine preparation was tested with or without adjuvants. Adjuvant Systems AS01(B) and AS03(A) were selected and tested for their capacity to elicit high humoral and cellular immune responses to WI-SARS vaccine. We evaluated the effect of vaccine dose and each adjuvant on immunogenicity and efficacy in mice, and the effect of vaccine dose with or without the AS01(B) adjuvant on the immunogenicity and efficacy in hamsters. Efficacy was evaluated by challenge with wild-type virus at early and late time points (4 and 18 wk post-vaccination). A single dose of vaccine with or without adjuvant was poorly immunogenic in mice; a second dose resulted in a significant boost in antibody levels, even in the absence of adjuvant. The use of adjuvants resulted in higher antibody titers, with the AS01(B)-adjuvanted vaccine being slightly more immunogenic than the AS03(A)-adjuvanted vaccine. Two doses of WI-SARS with and without Adjuvant Systems were highly efficacious in mice. In hamsters, two doses of WI-SARS with and without AS01(B) were immunogenic, and two doses of 2 μg of WI-SARS with and without the adjuvant provided complete protection from early challenge. Although antibody titers had declined in all groups of vaccinated hamsters 18 wk after the second dose, the vaccinated hamsters were still partially protected from wild-type virus challenge. Vaccine with adjuvant provided better protection than non-adjuvanted WI-SARS vaccine at this later time point. Enhanced disease was not observed in the lungs or liver of hamsters following SARS-CoV challenge, regardless of the level of serum neutralizing antibodies.
DOI: 10.1089/vim.2010.0028
PubMed: 20883165
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001617
- to stream PubMed, to step Curation: 001617
- to stream PubMed, to step Checkpoint: 001653
- to stream Ncbi, to step Merge: 002224
- to stream Ncbi, to step Curation: 002224
- to stream Ncbi, to step Checkpoint: 002224
- to stream Main, to step Merge: 002557
- to stream Main, to step Curation: 002523
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Immunogenicity and protective efficacy in mice and hamsters of a β-propiolactone inactivated whole virus SARS-CoV vaccine.</title><author><name sortKey="Roberts, Anjeanette" sort="Roberts, Anjeanette" uniqKey="Roberts A" first="Anjeanette" last="Roberts">Anjeanette Roberts</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Infectious Diseases, (NIAID), National Institutes of Health (NIH), Bethesda, Maryland 20892, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Infectious Diseases, (NIAID), National Institutes of Health (NIH), Bethesda, Maryland 20892</wicri:regionArea><wicri:noRegion>Maryland 20892</wicri:noRegion></affiliation></author><author><name sortKey="Lamirande, Elaine W" sort="Lamirande, Elaine W" uniqKey="Lamirande E" first="Elaine W" last="Lamirande">Elaine W. Lamirande</name></author><author><name sortKey="Vogel, Leatrice" sort="Vogel, Leatrice" uniqKey="Vogel L" first="Leatrice" last="Vogel">Leatrice Vogel</name></author><author><name sortKey="Baras, Benoit" sort="Baras, Benoit" uniqKey="Baras B" first="Benoît" last="Baras">Benoît Baras</name></author><author><name sortKey="Goossens, Genevieve" sort="Goossens, Genevieve" uniqKey="Goossens G" first="Geneviève" last="Goossens">Geneviève Goossens</name></author><author><name sortKey="Knott, Isabelle" sort="Knott, Isabelle" uniqKey="Knott I" first="Isabelle" last="Knott">Isabelle Knott</name></author><author><name sortKey="Chen, Jun" sort="Chen, Jun" uniqKey="Chen J" first="Jun" last="Chen">Jun Chen</name></author><author><name sortKey="Ward, Jerrold M" sort="Ward, Jerrold M" uniqKey="Ward J" first="Jerrold M" last="Ward">Jerrold M. Ward</name></author><author><name sortKey="Vassilev, Ventzislav" sort="Vassilev, Ventzislav" uniqKey="Vassilev V" first="Ventzislav" last="Vassilev">Ventzislav Vassilev</name></author><author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="RBID">pubmed:20883165</idno><idno type="pmid">20883165</idno><idno type="doi">10.1089/vim.2010.0028</idno><idno type="wicri:Area/PubMed/Corpus">001617</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001617</idno><idno type="wicri:Area/PubMed/Curation">001617</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001617</idno><idno type="wicri:Area/PubMed/Checkpoint">001653</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001653</idno><idno type="wicri:Area/Ncbi/Merge">002224</idno><idno type="wicri:Area/Ncbi/Curation">002224</idno><idno type="wicri:Area/Ncbi/Checkpoint">002224</idno><idno type="wicri:Area/Main/Merge">002557</idno><idno type="wicri:Area/Main/Curation">002523</idno><idno type="wicri:Area/Main/Exploration">002523</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Immunogenicity and protective efficacy in mice and hamsters of a β-propiolactone inactivated whole virus SARS-CoV vaccine.</title><author><name sortKey="Roberts, Anjeanette" sort="Roberts, Anjeanette" uniqKey="Roberts A" first="Anjeanette" last="Roberts">Anjeanette Roberts</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Infectious Diseases, (NIAID), National Institutes of Health (NIH), Bethesda, Maryland 20892, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Infectious Diseases, (NIAID), National Institutes of Health (NIH), Bethesda, Maryland 20892</wicri:regionArea><wicri:noRegion>Maryland 20892</wicri:noRegion></affiliation></author><author><name sortKey="Lamirande, Elaine W" sort="Lamirande, Elaine W" uniqKey="Lamirande E" first="Elaine W" last="Lamirande">Elaine W. Lamirande</name></author><author><name sortKey="Vogel, Leatrice" sort="Vogel, Leatrice" uniqKey="Vogel L" first="Leatrice" last="Vogel">Leatrice Vogel</name></author><author><name sortKey="Baras, Benoit" sort="Baras, Benoit" uniqKey="Baras B" first="Benoît" last="Baras">Benoît Baras</name></author><author><name sortKey="Goossens, Genevieve" sort="Goossens, Genevieve" uniqKey="Goossens G" first="Geneviève" last="Goossens">Geneviève Goossens</name></author><author><name sortKey="Knott, Isabelle" sort="Knott, Isabelle" uniqKey="Knott I" first="Isabelle" last="Knott">Isabelle Knott</name></author><author><name sortKey="Chen, Jun" sort="Chen, Jun" uniqKey="Chen J" first="Jun" last="Chen">Jun Chen</name></author><author><name sortKey="Ward, Jerrold M" sort="Ward, Jerrold M" uniqKey="Ward J" first="Jerrold M" last="Ward">Jerrold M. Ward</name></author><author><name sortKey="Vassilev, Ventzislav" sort="Vassilev, Ventzislav" uniqKey="Vassilev V" first="Ventzislav" last="Vassilev">Ventzislav Vassilev</name></author><author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name></author></analytic><series><title level="j">Viral immunology</title><idno type="eISSN">1557-8976</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic (administration & dosage)</term><term>Animals</term><term>Antibodies, Neutralizing (blood)</term><term>Antibodies, Viral (blood)</term><term>Cricetinae</term><term>Disinfectants (pharmacology)</term><term>Female</term><term>Immunization, Secondary (methods)</term><term>Liver (pathology)</term><term>Lung (pathology)</term><term>Mesocricetus</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Propiolactone (pharmacology)</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Severe Acute Respiratory Syndrome (prevention & control)</term><term>Survival Analysis</term><term>Vaccination (methods)</term><term>Vaccines, Inactivated (immunology)</term><term>Viral Vaccines (immunology)</term><term>Virus Inactivation</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adjuvants immunologiques (administration et posologie)</term><term>Analyse de survie</term><term>Animaux</term><term>Anticorps antiviraux (sang)</term><term>Anticorps neutralisants (sang)</term><term>Cricetinae</term><term>Désinfectants (pharmacologie)</term><term>Femelle</term><term>Foie (anatomopathologie)</term><term>Inactivation virale</term><term>Mesocricetus</term><term>Poumon (anatomopathologie)</term><term>Propiolactone (pharmacologie)</term><term>Rappel de vaccin ()</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Syndrome respiratoire aigu sévère ()</term><term>Syndrome respiratoire aigu sévère (immunologie)</term><term>Vaccination ()</term><term>Vaccins antiviraux (immunologie)</term><term>Vaccins inactivés (immunologie)</term><term>Virus du SRAS (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Adjuvants, Immunologic</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Neutralizing</term><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Vaccines, Inactivated</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Disinfectants</term><term>Propiolactone</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Adjuvants immunologiques</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Foie</term><term>Poumon</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term><term>Vaccins antiviraux</term><term>Vaccins inactivés</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Immunization, Secondary</term><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Liver</term><term>Lung</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Désinfectants</term><term>Propiolactone</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term><term>Anticorps neutralisants</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cricetinae</term><term>Female</term><term>Mesocricetus</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Survival Analysis</term><term>Virus Inactivation</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Analyse de survie</term><term>Animaux</term><term>Cricetinae</term><term>Femelle</term><term>Inactivation virale</term><term>Mesocricetus</term><term>Rappel de vaccin</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Syndrome respiratoire aigu sévère</term><term>Vaccination</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The immunogenicity and efficacy of β-propiolactone (BPL) inactivated whole virion SARS-CoV (WI-SARS) vaccine was evaluated in BALB/c mice and golden Syrian hamsters. The vaccine preparation was tested with or without adjuvants. Adjuvant Systems AS01(B) and AS03(A) were selected and tested for their capacity to elicit high humoral and cellular immune responses to WI-SARS vaccine. We evaluated the effect of vaccine dose and each adjuvant on immunogenicity and efficacy in mice, and the effect of vaccine dose with or without the AS01(B) adjuvant on the immunogenicity and efficacy in hamsters. Efficacy was evaluated by challenge with wild-type virus at early and late time points (4 and 18 wk post-vaccination). A single dose of vaccine with or without adjuvant was poorly immunogenic in mice; a second dose resulted in a significant boost in antibody levels, even in the absence of adjuvant. The use of adjuvants resulted in higher antibody titers, with the AS01(B)-adjuvanted vaccine being slightly more immunogenic than the AS03(A)-adjuvanted vaccine. Two doses of WI-SARS with and without Adjuvant Systems were highly efficacious in mice. In hamsters, two doses of WI-SARS with and without AS01(B) were immunogenic, and two doses of 2 μg of WI-SARS with and without the adjuvant provided complete protection from early challenge. Although antibody titers had declined in all groups of vaccinated hamsters 18 wk after the second dose, the vaccinated hamsters were still partially protected from wild-type virus challenge. Vaccine with adjuvant provided better protection than non-adjuvanted WI-SARS vaccine at this later time point. Enhanced disease was not observed in the lungs or liver of hamsters following SARS-CoV challenge, regardless of the level of serum neutralizing antibodies.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country></list><tree><noCountry><name sortKey="Baras, Benoit" sort="Baras, Benoit" uniqKey="Baras B" first="Benoît" last="Baras">Benoît Baras</name><name sortKey="Chen, Jun" sort="Chen, Jun" uniqKey="Chen J" first="Jun" last="Chen">Jun Chen</name><name sortKey="Goossens, Genevieve" sort="Goossens, Genevieve" uniqKey="Goossens G" first="Geneviève" last="Goossens">Geneviève Goossens</name><name sortKey="Knott, Isabelle" sort="Knott, Isabelle" uniqKey="Knott I" first="Isabelle" last="Knott">Isabelle Knott</name><name sortKey="Lamirande, Elaine W" sort="Lamirande, Elaine W" uniqKey="Lamirande E" first="Elaine W" last="Lamirande">Elaine W. Lamirande</name><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name><name sortKey="Vassilev, Ventzislav" sort="Vassilev, Ventzislav" uniqKey="Vassilev V" first="Ventzislav" last="Vassilev">Ventzislav Vassilev</name><name sortKey="Vogel, Leatrice" sort="Vogel, Leatrice" uniqKey="Vogel L" first="Leatrice" last="Vogel">Leatrice Vogel</name><name sortKey="Ward, Jerrold M" sort="Ward, Jerrold M" uniqKey="Ward J" first="Jerrold M" last="Ward">Jerrold M. Ward</name></noCountry><country name="États-Unis"><noRegion><name sortKey="Roberts, Anjeanette" sort="Roberts, Anjeanette" uniqKey="Roberts A" first="Anjeanette" last="Roberts">Anjeanette Roberts</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002523 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002523 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:20883165
|texte= Immunogenicity and protective efficacy in mice and hamsters of a β-propiolactone inactivated whole virus SARS-CoV vaccine.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:20883165" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |